{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:19Z","timestamp":1787026999724,"version":"build-2736575974"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Until now there has been no comprehensive data from extensive samples to evaluate the therapeutic potential of inetetamab in metastatic breast cancer (MBC) patients who had a history of trastuzumab treatment. Some previous studies had either small sample sizes from single-center, or partial enrolled patients without prior exposure to trastuzumab. This study aimed to provide a deep analysis of inetetamab-based therapy in this specific population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter retrospective study collected clinicopathological data from a total of 500 patients between Jul 2020 and Oct 2023. Progression-free survival (PFS) was estimated as the primary endpoint. Secondary endpoints included objective response rate (ORR), disease control rate (DCR) and adverse events (AEs). The association of risk factors with the effect of inetetamab treatment on PFS was evaluated using Cox proportional hazards regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the overall cohort, we observed a median PFS of 8.0 months, an ORR of 28.6% and a DCR of 89.2% (median treatment line: third line). Meanwhile, patients who received a combination treatment regime of inetetamab + tyrosine kinase inhibitors (TKIs) + chemotherapy achieved the most prolonged PFS of 9.0 months and the higher ORR of 29.3%. Ki67 index, distant lymph nodes metastasis and treatment strategy were independent predictors of PFS. The most common all-grade AEs were neutropenia (182\/500, 36.4%) and leukopenia (157\/500, 31.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inetetamab was promising in HER2-positive MBC patients who had prior exposure to trastuzumab, offering a new option for patients with a prior failure of trastuzumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1496371","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:33:18Z","timestamp":1756791198000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab"],"prefix":"10.3389","volume":"15","author":[{"given":"Yangyang","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxi","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"E","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20231009-00123","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Chin J Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.12037\/YXQY.2024.06-01","article-title":"Interpretation on the global cancer statistics of GLOBOCAN 2020","volume":"13","author":"Cao","year":"2021","journal-title":"Chin J Front Med Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.13267\/j.cnki.syzlzz.2023.079","article-title":"Update and interpretation of CSCO guidelines in 2023: HER2-positive advanced breast cancer","volume":"38","author":"Sun","year":"2023","journal-title":"J Prac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.10.010","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis","volume":"66","author":"Zhu","year":"2022","journal-title":"Breast"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1042","article-title":"Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial","volume":"41","author":"Lv","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molimm.2020.01.009","article-title":"A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action","volume":"119","author":"Zhang","year":"2020","journal-title":"Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.11669\/cpj.2015.12.014","article-title":"Evaluation of critical quality attributes of an anti-HER2 humanized monoclonal antibody drug","volume":"50","author":"Wang","year":"2015","journal-title":"Chin Pharm J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20200116-00105","article-title":"Phase III randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study","volume":"100","author":"Bian","year":"2020","journal-title":"Natl Med J China"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/tbcr-21-42","article-title":"Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study","volume":"3","author":"Wang","year":"2022","journal-title":"Transl Breast Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.103597","article-title":"Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody","volume":"72","author":"Liu","year":"2023","journal-title":"Breast"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1136380","article-title":"Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00025-x","article-title":"Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis","volume":"49","author":"Sun","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines\u00ae Insights: breast cancer, version 4. 2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S335934","article-title":"HER2-directed therapy in advanced breast cancer: benefits and risks","volume":"19","author":"Mand\u00f3","year":"2023","journal-title":"Onco Targets Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e13015","article-title":"Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2024.2335714","article-title":"Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer","volume":"37","author":"Zhou","year":"2025","journal-title":"J Chemother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05406-6","article-title":"Long-term outcome with targeted therapy in advanced\/metastatic HER2-positive breast cancer: the Royal Marsden experience","volume":"178","author":"Battisti","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: A review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05728-w","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study","volume":"182","author":"Xu","year":"2020","journal-title":"Breast Cancer Res Treat"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1496371\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:33:24Z","timestamp":1756791204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1496371\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1496371"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1496371","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1496371"}}